Cheryl Arrowsmith

Cheryl H. Arrowsmith is a Canadian structural biologist and is the Chief Scientist at the Toronto laboratory of the Structural Genomics Consortium. Her contributions to protein structural biology[1] includes the use of NMR and X-ray crystallography to pursue structures of proteins on a proteome wide scale.

Cheryl Arrowsmith
NationalityCanadian
Alma materUniversity of Toronto
Scientific career
FieldsStructural biology
InstitutionsStructural Genomics Consortium

She received her Ph.D. in chemistry at the University of Toronto in 1987 and post-doctoral training at Stanford University working with Oleg Jardetzky. One of her areas of interest is the tumour suppressor p53 and related proteins.[2]

Her current research is to determine the 3-dimensional structures of human proteins of therapeutic relevance by structural proteomics.[3] She made significant contributions to epigenetic signaling with her highest cited paper is "Epigenetic protein families: a new frontier for drug discovery"[4] cited at 802 times, according to Google Scholar.[5]

Arrowsmith was named a Fellow of the American Association for the Advancement of Science (AAAS) in 2015.[6]

References
  1. "Cheryl H. Arrowsmith". uhnresearch.ca. Retrieved December 27, 2017.
  2. "Cheryl Arrowsmith". utoronto.ca. Retrieved December 27, 2017.
  3. Chandonia JM, Brenner SE (January 2006). "The impact of structural genomics: expectations and outcomes". Science. 311 (5759): 347–51. Bibcode:2006Sci...311..347C. doi:10.1126/science.1121018. PMID 16424331.
  4. Cheryl H. Arrowsmith, Chas Bountra, Paul V. Fish, Kevin Lee & Matthieu Schapira. Epigenetic protein families: a new frontier for drug discovery. Nature Reviews Drug Discovery 11, 384–400 (2012)
  5. "Cheryl Arrowsmith". Retrieved December 27, 2017.
  6. "Arrowsmith named AAAS Fellow". utoronto.ca. Retrieved December 27, 2017.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.